Oral Form of Anti-cancer Agent Shows Promise in Treating Sarcoma

	Tweet

The Institute for Drug Development, a division of The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, today announced results of a Phase I dose-ranging study of oral deforolimus, a drug that was effective as an intravenous therapy in previous studies.

These data provide the rationale for selection of the oral dose and administration schedule in the ongoing Phase III SUCCEED trial of deforolimus for the treatment of advanced metastatic sarcomas to help improve patients’ quality of life.

The phase I study will be presented in full at the annual meeting of the American Society of Clinical Oncology (ASCO), to be held in Chicago from May 31 to June 3.

The data from this trial of 147 patients with solid tumors resistant to therapy will be presented in an oral session by clinical investigator and assistant professor Monica M. Mita, M.D., of the CTRC at the UT Health Science Center.

The presentation, titled “Deforolimus trial 106 – A Phase 1 trial evaluating 7 regimens of oral deforolimus (AP23573, MK-8669),” will be given by Dr. Mita at 1:15 pm (CDT) on Saturday, May 31, 2008, during the Clinical Science Symposium on PI-3 Kinase/mTOR Directed Agents.

“These results present us with important information about deforolimus’ oral formulation, providing an alternative route of administration that has the potential to offer greater patient convenience and treatment flexibility than the intravenous form,” Dr. Mita said. “I also am very pleased to see that the anti-tumor activity and safety profile appear consistent with our previous clinical experience with the intravenous formulation of deforolimus.”

Oral deforolimus, an mTOR inhibitor that regulates normal cell growth and slows or stops the growth of cancer cells, was found to have a safety and anti-tumor activity consistent with the intravenous form.

This non-randomized, open-label, dose-escalation Phase I study was designed to measure tolerability and anti-tumor activity of oral deforolimus administered in seven different dosing regimens. The study found the dose of 40 mg QDx5 each week was an active and well-tolerated regimen. The daily and monthly exposure to oral deforolimus varied in each group, along with the duration of weekly “drug holidays.”

As in all previous clinical trials with the intravenous formulation, the only dose-limiting toxicity for all oral regimens was apthous ulcer-like mouth sores, which were reversible by dose reduction or symptomatic therapy. The selected optimal dose maximized exposure to oral deforolimus while maintaining a safety profile that was generally well tolerated by patients.

About the CTRC:

The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is one of the nation’s leading academic research and treatment centers, serving more than 4.4 million people in the high-growth corridor of Central and South Texas including Austin, San Antonio, Laredo and the Rio Grande Valley. CTRC is one of a few elite cancer centers in the country to be named a National Cancer Institute (NCI) Designated Cancer Center, and is one of only three in Texas. CTRC handles more than 120,000 patient visits each year and is a world leader in developing new drugs to treat cancer. The CTRC Institute for Drug Development (IDD) is internationally recognized for conducting the largest oncology Phase I clinical drug trials program in the world, and participated in the clinical and/or preclinical development of many of the cancer drugs approved by the U.S. Food & Drug Administration.

Source: University of Texas Health Science Center at San Antonio

RELATED STORIES:
Study Quantifies Racial Disparities in Cancer Mortality Rates   Alcohol and cancer: is drinking the new smoking?   Researchers Develop and Improve Techniques for Treating Cancer   Computer-based tool to improve diagnosis and prognosis for cancer patients   New Markers of Prognosis for Cancer Therapies Highlighted   Mistletoe extract may treat bladder cancer   Cancer survivors may not be getting the help they need to stop smoking   Technology uses tobacco plants to fight cancer   Risk of cancer increases with exposure to low-dose radiation   No alarm on fluoride: cancer risk unproven   Mayo Clinic Researchers Find That Protein Believed to Protect Against Cancer Has a Mr. Hyde Side   DNA differences may influence risk of Hodgkin disease   New Hope in Cancer Vaccines Emerges as Novel Therapies are Developed and Tested   Cancer may require simpler genetic mutations than previously thought   Immunotherapy for tumors key topic at cancer meeting   Study finds way to predict when cancer will spread   New Algorithm Matches Tumor Cells to Best Anticancer Treatments   Virginia Tech engineers introduce thermotherapy as a chemotherapy alternative   Working with poultry linked to certain cancers   Telephone Calls Increase Cancer Screening Rates   New technique can be breakthrough for early cancer diagnosis   Ben-Gurion U. researchers reveal connection between cancer and human evolution

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]